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Background:  The interaction between genetic, epigenetic and environmental factors plays 28 
an important role in the aetiology of hypertension. GWAS and observational studies link the 29 
C677T polymorphism in methylenetetrahydrofolate reductase (MTHFR) with hypertension, 30 
while riboflavin, the MTHFR cofactor, has been shown to reduce blood pressure and global 31 
DNA methylation in homozygous (TT genotype) individuals. It is currently unclear whether 32 
riboflavin modulates DNA methylation of other hypertension-related genes. 33 
Objectives: To compare DNA methylation of hypertension-related genes in adults stratified 34 
by MTHFR genotype and effect of riboflavin intervention in adults with the variant MTHFR 35 
677TT genotype. 36 
Methods: Pyrosequencing was carried out for hypertension-related genes (ACE, AGTR1, 37 
GCK, GNA12, IGF2, MMP9 and NOS3) in blood samples from participants in previous trials 38 
(CC, n = 40; TT, n = 40). The effect of intervention with riboflavin (1.6mg/d for16 weeks) or 39 
placebo on DNA methylation was investigated in adults with the variant MTHFR 677TT 40 
genotype (n=80). 41 
Results: Individuals with the MTHFR 677TT v CC genotype had significantly higher average 42 
DNA methylation at NOS3 (+1.66%, P = 0.044). In response to riboflavin supplementation in 43 
TT individuals, there was an increase in average DNA methylation at IGF2 (+1.09%, P = 44 
0.019) and a decrease at ACE (-0.44%, P=0.021) in females only. Specific CpG sites were 45 
hypomethylated in GNA12 and hypermethylated in AGTR1.  46 
Conclusion: This study provides the first RCT evidence that riboflavin alters DNA 47 
methylation of hypertension-related genes in adults with the MTHFR 677TT genotype, 48 
providing some insight into mechanisms linking hypertension with the genotype-specific 49 
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1.0 INTRODUCTION  55 
Hypertension is a global health challenge and a major risk factor for cardiovascular diseases, 56 
particularly stroke  (1,2). Genetic variation contributes to the risk of developing high blood 57 
pressure with multiple genetic factors accounting for 30-70% of blood pressure (BP) 58 
variability in hypertension (3,4). It does not however account for all blood pressure 59 
variability and therefore a number of additional hypotheses have been proposed, with 60 
epigenetics emerging as a strong candidate (5). Evidence from both genome-wide association 61 
studies (GWAS) (6,7) and epidemiological studies (8) implicates the gene encoding the 62 
folate-metabolizing enzyme methylenetetrahydrofolate reductase (MTHFR) in hypertension 63 
(9). Previous randomised controlled trials (RCT) from our research group have confirmed 64 
that the MTHFR C677T polymorphism is associated with higher blood pressure and have 65 
demonstrated that the blood pressure phenotype can be lowered in individuals with the 66 
variant MTHFR 677TT genotype by supplementation with riboflavin, the MTHFR co-factor 67 
(10–12). The biological mechanisms linking this polymorphism with blood pressure, and the 68 
blood pressure-lowering effect of riboflavin in affected individuals, are not well understood 69 
(13), but may involve alterations in DNA methylation of specific genes involved in blood 70 
pressure regulation.  In support of this hypothesis, we have recently shown that global 71 
methylation is higher in 677TT individuals than their CC counterparts and can be reduced by 72 
riboflavin supplementation (14).   73 
Evidence from the literature indicates that perturbation of DNA methylation leads to genomic 74 
instability and transcriptional repression and thereby influencing disease aetiology (15,16). 75 
These perturbations result from imbalances in the supply of nutrients in one-carbon 76 
metabolism, the main metabolic pathway for generating methyl groups for biological 77 
reactions including DNA methylation (17,18). Alterations in DNA methylation both globally 78 
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and at key gene loci, have also been implicated in hypertension (19). Furthermore, 79 
cardiovascular disease (CVD) has been identified as an age-related condition linked to 80 
epigenetic age acceleration in blood using the DNA methylation-based Phenotypic Age 81 
measure (PhenoAge) (20), which also demonstrates a positive correlation between systolic 82 
blood pressure and epigenetic age. 83 
This study focuses on key genes implicated in hypertension including angiotensin I 84 
converting enzyme (ACE), angiotensin receptor 1 (AGTR1), glucokinase (GCK), guanine 85 
nucleotide- binding protein alpha-12 gene (GNA12), insulin-like growth factor II (IGF2), 86 
matrix metalloproteinase 9 (MMP9) and nitric oxide synthase 3 (NOS3). These genes are 87 
involved in blood pressure regulation through their functions in the renin-angiotensin system, 88 
smooth muscle cell regulation and endothelial function (21–23). We hypothesised that DNA 89 
methylation of genes involved in hypertension-related pathways would differ by MTHFR 90 
genotype and be modulated by riboflavin, the MTHFR cofactor, in individuals with the 91 
variant MTHFR 677TT genotype. To explore this hypothesis, the aims of the current study 92 
were to investigate DNA methylation of key hypertension-related genes in adults stratified by 93 
MTHFR genotype, and to examine the effect of riboflavin supplementation on DNA 94 
methylation of hypertension pathway loci specifically in individuals with the MTHFR 677TT 95 
genotype.  96 
 97 
2.0 MATERIALS AND METHODS 98 
2.1 Participants and study design 99 
Stored samples from participants pre-screened for the MTHFR C677T polymorphism, who 100 
had previously consented and participated in targeted RCTs, investigating riboflavin as a 101 
treatment for hypertension in individuals with the MTHFR 677TT genotype, were accessed 102 
for the current investigation. Samples for the present analysis were drawn from three identical 103 
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cohorts namely, the Genetic and Vitamin follow up study (Genovit-FCBMA-15-070), the 104 
Genetic and Vitamin ten year follow up study (GENOVIT10 -UUREC/12/0338) and the 105 
optimisation of RIBOflavin Status in Hypertensive Adults with a Genetic predisposition to 106 
Elevated Blood pressure study (RIBOGENE - ORECNI/12/0136). Sampling from these three 107 
trials facilitated access to the required number of age- and sex-matched samples from both 108 
placebo and treatment groups. All studies were conducted at the Nutrition Innovation Centre 109 
for food and Health (NICHE). Lifestyle data, blood pressure, anthropometry and blood 110 
samples were collected as part of all three studies using identical standard operating 111 
procedures. Riboflavin status, measured by the functional biomarker, erythrocyte glutathione 112 
reductase activity coefficient (EGRac) was examined in all the samples (10,11). The EGRac 113 
assay is a functional assay which measures the activity of the enzyme glutathione reductase in 114 
washed red cells before and after in vitro reactivation with its prosthetic group FAD. EGRac 115 
is calculated as a ratio of FAD-stimulated to unstimulated enzyme activity, with values <1.3 116 
generally indicative of optimal riboflavin status was conducted using identical standard 117 
operating procedures. Furthermore, each study utilised the same inclusion and exclusion 118 
criteria. Participants were excluded if they had a history of gastrointestinal, hepatic, renal, or 119 
haematological disorders, or were taking B-vitamin supplements, anticonvulsant therapy, or 120 
any other drugs known to interfere with folate or B-vitamin metabolism (10–12). Ethical 121 
approval was granted for each of the studies and was conducted in accordance with the 122 
Declaration of Helsinki. All the participants provided informed consent. Additional ethical 123 
approval was granted by University of Ulster Research Ethics Committee Northern Ireland 124 






2.2 Study design 129 
DNA methylation analysis for this study was carried out in two phases: in an observational 130 
phase, differences in gene-specific methylation were compared between the two MTHFR 131 
C677T genotypes (i.e. CC, n = 40 versus TT, n = 40). In the intervention phase, changes in 132 
gene-specific DNA methylation were examined in participants with the TT genotype only 133 
(placebo, n = 40; riboflavin, n = 40) in response to intervention with riboflavin (1.6mg/d) or 134 
placebo for 16weeks. The flow diagram of the study design is shown in Supplementary 135 
Figure 1. Sample size calculations for the present analysis was carried out using the G Power 136 
3.1.9.4 statistical power calculator (version 3) (24). Based on power calculations  using data 137 
from Bollati et al (25), it was estimated that 39 participants per group would be able to 138 
discriminate differences of 3.4% in DNA methylation with a power of 80%, at α = 0.05 and 139 
effect size of 0.65.  140 
 141 
2.3 DNA Methylation Analysis 142 
2.3.1 Selection of candidate genes for DNA methylation analysis 143 
A candidate gene approach focusing on hypertension pathway loci was used to select a set of 144 
genes directly involved in blood pressure regulation or shown to be associated with 145 
hypertension in the literature (Supplementary Table 1). 146 
2.3.2 Genomic DNA extraction 147 
For the current analysis, genomic DNA was extracted from 200µl of stored peripheral blood 148 
leukocyte samples using the Qiagen QIAamp DNA blood mini kit (Qiagen, UK) according to 149 
the manufacturer’s protocol (26). Genomic DNA samples were electrophoresed on a 1% 150 
(w/v) agarose gel to examine quality. The purity of the samples was evaluated, and 151 
concentrations quantified using the NanodropND1000 spectrophotometer (Labtech 152 
International, Ringmer, UK). 153 
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2.3.3 Bisulphite Conversion of Genomic DNA 154 
500ng of genomic DNA was subsequently bisulphite converted using the EZ DNA 155 
methylation kit (Zymo Research Corporation, California) according to manufacturer’s 156 
protocol (27) using the EZ DNA methylation kit. 157 
2.3.4 Pyrosequencing 158 
Commercially available predesigned methylation assays from Qiagen UK were used for 159 
bisulphite PCR and pyrosequencing for the following loci: ACE (PM00181398), AGTR1 160 
(PM00014875), GNA12 (PM00127925), MMP9 (PM00079191) and NOS3 (PM00129220) 161 
while assays for IGF2 and GCK were based on previously published primer sets from 162 
previous studies which have examined these specific regions (28–30). Details of the assays, 163 
chromosomal location and number of CpGs examined are provided in Supplementary Table 164 
2. After bisulphite conversion, DNA amplicons were amplified by PCR using the PyroMark 165 
PCR kit (Qiagen, UK) according to manufacturer’s protocol. Each 25µl PCR reaction mix 166 
consisted of 12.5µl master mix, 2.5µl coral load, 5.5µl nuclease-free water, 2.5µl each of 167 
10µM primer set and 2µl each of bisulphite converted DNA. PCR was then carried out under 168 
the following conditions: hot start of 95⁰C for 15 minutes, followed by 45 cycles of 94⁰C for 169 
30 seconds, 56⁰C for 30 seconds, 72⁰C for 30s and a final elongation of 10 minutes at 72⁰C. 170 
The PCR products were subsequently electrophoresed on a 1% (w/v) agarose gel to check the 171 
integrity of PCR products. DNA methylation in samples was analysed using the PyroMark 172 
Q24 pyrosequencing instrument (Qiagen, UK). Enzymes, substrates and nucleotides from the 173 
PyroMark Gold Q24 kit (Qiagen UK) were used. Levels of methylation at each CpG site 174 
were analysed using the PyroMark Q24 software (31). As an additional control, bisulphite 175 
DNA controls from EpiTect PCR Control DNA (Qiagen, UK) that contained fully methylated 176 
as well as fully unmethylated DNA was included in the analysis to ensure that the instrument 177 
detected the full range of methylation values. 178 
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2.4 Statistical analyses 179 
Statistical Package for the Social Sciences (SPSS) IBM Statistics (version 25, SPSS UK Ltd 180 
Chertsey, UK) was used to statistically analyse the data obtained from the pyrosequencing 181 
analysis. QQ-plots and the Kolmogorov-Smirnov test were used to verify the normality of 182 
continuous variables. Chi-square tests were used for analysing baseline categorical data while 183 
continuous variables were analysed using independent t-tests. Baseline differences in gene-184 
specific methylation between the two MTHFR C677T genotypes were analysed using one-185 
way analysis of covariance (ANCOVA) adjusting for age, sex, smoking status and study 186 
cohort. The treatment effect of supplementation with riboflavin or placebo over time on 187 
riboflavin biomarker status, blood pressure and gene-specific methylation in participants with 188 
the MTHFR 677TT genotype only was analysed using mixed between-within analysis of 189 
variance adjusting for age, sex, smoking status and study cohort as covariates. The between-190 
patient factor was the intervention group (placebo versus riboflavin), and the within-patient 191 
factor was time (pre and post-intervention). Furthermore, multiple linear regression adjusting 192 
for covariates was carried out to identify the determinants of gene-specific methylation. All 193 
statistical tests were carried out at the 95% confidence interval and in all analyses p-values 194 
less than 0.05 were considered statistically significant. 195 
 196 
 197 
3.0 RESULTS 198 
3.1 Baseline characteristics of participants 199 
Age- and sex-matched participant samples were accessed for the observational (n = 80) and 200 
intervention (n = 80) phases of this study. Demographic characteristics showed that the 201 
average age of participants was 57 years and that baseline characteristic including age, sex, 202 
BMI and smoking status were not different between MTHFR 677CC and TT individuals 203 
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(Table 1). In the observational stage of the study, as expected, individuals with the TT 204 
genotype had significantly higher systolic (+11.1 mmHg; P = 0.005) and diastolic blood 205 
pressure (+5.1 mmHg; P = 0.022) compared to participants with CC genotype (10,11).  206 
In individuals with the MTHFR 677TT genotype, who were supplemented with riboflavin, 207 
biomarker status (EGRac), systolic and diastolic blood pressure were not significantly 208 
different between treatment groups, prior to intervention. Following intervention, riboflavin 209 
biomarker status improved as expected (indicated by a significant decrease (-0.10 ± 0.01, P < 210 
0.001) in EGRac) compared to no change in the placebo group. Furthermore, consistent with 211 
previous studies which contributed these convenience samples (10,11), supplementation with 212 
riboflavin resulted in significant decreases in systolic (-7.9 mmHg; P < 0.001) and diastolic (-213 
3.8 mmHg; P < 0.019) blood pressure in adults with the MTHFR 677TT in this combined 214 
cohort (results not shown). 215 
3.2 Differences in DNA methylation in individuals stratified by MTHFR C677T 216 
genotype 217 
DNA methylation analysis of the candidate hypertension-related genes indicate an overall 218 
trend toward hypermethylation at several loci including ACE, AGTR1, GCK, MMP9 and 219 
NOS3 in individuals with the MTHFR 677TT genotype compared to the CC genotype (Table 220 
2). Average DNA methylation levels were significantly higher at NOS3 (1.66%, P = 0.044) in 221 
the TT genotype compared to individuals with the CC genotype after adjusting for age, sex, 222 
smoking status and study cohort. Significant CpG site-specific differences were observed at 223 
CpG2 of AGTR1 and CpG1 of GNA12. Examination of sex-specific differences in 224 
methylation between the MTHFR genotypes showed that methylation differences observed at 225 
NOS3 was marginally significant in females but not in males (Table 2). Multiple linear 226 
regression adjusting for covariates was used to identify the determinants of gene-specific 227 
methylation in adults with the MTHFR C677T polymorphism (CC and TT genotypes) at 228 
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baseline in the observational stage of this analysis (Table 3). MTHFR genotype was 229 
significantly associated with methylation at NOS3 (β = 0.256, P = 0.031, R2 = 0.102) and 230 
AGTR1 (β = 0.264, P = 0.026, R2 = 0.096), while methylation at GCK loci was significantly 231 
associated with age (β = 0.321, P = 0.004, R2 = 0.161) and sex (β = 0.224, P = 0.047, R2 = 232 
0.161). No significant associations with baseline determinants were demonstrated for other 233 
locations. 234 
3.3 Effect of riboflavin supplementation on gene-specific methylation in adults with the 235 
MTHFR 677TT genotype 236 
 Supplementation with riboflavin, resulted in increased overall methylation at IGF2 (+1.08%, 237 
P = 0.019) compared with placebo. Increased methylation was observed at CpG1 of AGTR1, 238 
however, methylation decreased at CpG2 and CpG4 of GNA12 in TT participants receiving 239 
riboflavin compared to placebo. Stratification of the analysis by sex, indicated increased 240 
methylation in response to riboflavin supplementation at IGF2 (+1.44%; P = 0.017) 241 
compared with placebo in males but not females. However, decreased methylation was 242 
observed at ACE (-0.44%; P = 0.021) in females but not males (Table 4). Multiple linear 243 
regression analysis, focused specifically on individuals with the MTHFR 677TT genotype in 244 
the intervention stage of the study, showed that riboflavin treatment was a determinant of 245 
IGF2 methylation (β = 0.265, P = 0.021, R2 = 0.106). No other genes showed any significant 246 
interaction with any of the baseline determinants. 247 
 248 
 249 
4.0 DISCUSSION 250 
This study is the first to show that DNA methylation is altered by intervention with riboflavin 251 
at a number of important candidate genes related to hypertension in adults with the MTHFR 252 
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677TT genotype using samples from previously conducted RCTs. The results show that 253 
riboflavin supplementation compared with placebo resulted in significant increases in average 254 
IGF2 methylation and CpG site-specific alterations in methylation at AGTR1 and GNA12 loci 255 
in adults with the TT genotype. Additionally, at baseline, significantly higher methylation in 256 
TT compared to CC individuals at NOS3 was observed with significant sex differences 257 
appearing to indicate that this difference is driven by females.  258 
Riboflavin supplementation compared with placebo in individuals with the MTHFR 677TT 259 
genotype, showed increased average methylation at IGF2, which was also demonstrated in 260 
the linear regression model which showed riboflavin treatment as the sole determinant of 261 
methylation of IGF2. Although no other study, to our knowledge, has investigated the role of 262 
riboflavin in modulating DNA methylation at IGF2, studies investigating the epigenetic 263 
effects of other B-vitamins, mainly folic acid and vitamin-B12, in various populations report 264 
significant increases in IGF2 methylation in response to supplementation (28,32) supporting 265 
the findings of this study. IGF2 is a paternally expressed imprinted gene with well-266 
established physiological roles in growth and development. Polymorphisms of IGF2 have 267 
been related to vascular risk factors and hypertension (33,34). Furthermore, IGF2 functions 268 
as part of the insulin-like growth factor (IGF) system which plays complex roles in nutrient-269 
sensitive pathways and may indirectly influence blood pressure through the regulation of 270 
cardiac muscles (35). Alterations in methylation could therefore potentially impact IGF2 271 
expression with implications for blood pressure regulation. Although significant, the changes 272 
in methylation observed at IGF2 are very small, however, the magnitude of change is in 273 
agreement with previous studies showing that small changes in methylation can result in 274 
transcriptional alterations including at imprinted genes (36). Further functional studies are 275 
required to investigate the implications of our findings on gene expression. Apart from 276 
overall changes in average methylation, we observed significant decreases at specific CpG 277 
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sites within the GNA12 loci. Similarly, in an RCT investigating supplementation of folic acid 278 
and vitamin B-12 on genome-wide methylation, differential methylation was observed at the 279 
GNA12 locus, with methylation shown to decrease in response to supplementation with folic 280 
acid and vitamin B12 in comparison to placebo in adults (37).  281 
While associations between polymorphisms in the NOS3 gene and cardiovascular disease 282 
have been widely studied, methylation at NOS3 in individuals with the MTHFR C677T has 283 
not been extensively investigated. It is widely accepted that CpG islands at promoters of 284 
housekeeping genes are usually unmethylated allowing transcription. Hypermethylation at the 285 
NOS3 loci as observed in individuals with the MTHFR 677TT genotype has the potential to 286 
inhibit the expression of this gene and thereby influencing its function in regulating blood 287 
pressure. NOS3 is a key regulator of vasotone, platelet aggregation and blood pressure 288 
(21,22,38). Furthermore, mendelian randomisation studies in stroke patients indicate that 289 
genetic variation in the nitric oxide synthase pathway affects stroke risk via variations in 290 
blood pressure (39). Surprisingly, there were no changes in methylation at the CpGs analysed 291 
at the NOS3 locus in this study in response to riboflavin supplementation. It is, however, 292 
likely that other CpGs at this locus were altered by intervention with riboflavin, indicated by 293 
preliminary data from an ongoing epigenome-wide study. This further highlights the 294 
limitation of the candidate gene approach of this study.  Furthermore, it also suggests that 295 
other mechanisms in addition to methylation may be modulating the effect of riboflavin on 296 
blood pressure in adults with the MTHFR 677TT genotype. For, example it has been 297 
postulated that endothelial nitric oxide synthase (eNOS) may provide a link between MTHFR 298 
677TT genotype and blood pressure (40). 299 
Consistent with findings of the present study, several studies have reported sex- and age- 300 
specific differences in methylation at several gene loci (41,42). These sex-specific differences 301 
could be owing to different mechanisms and pathogenic processes involved in blood pressure 302 
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regulation by these genes in males and females. These findings are in general agreement with 303 
studies investigating blood pressure which also showed that metabolic and haemodynamic 304 
abnormalities associated with hypertension differed markedly between sexes (43). For 305 
example, while a cardiac phenotype was associated with elevated blood pressure and 306 
hypertension in males, a vascular phenotype characterised by elevated peripheral vascular 307 
resistance was more prominent in females (43). Furthermore, similar to findings from Xu and 308 
colleagues (30) who reported significant correlations between GCK gene body methylation 309 
and aging, multiple linear regression in the present study identified age and sex as 310 
determinants of methylation at the GCK locus although no significant differences were 311 
observed between MTHFR genotypes. Changes in methylation have been shown to correlate 312 
with age providing a biological marker for ageing (44) and these sites could play important 313 
roles in disease such as hypertension. It must be noted that although overall changes may not 314 
be seen across all CpGs within a gene, site-specific alterations may still occur, and these site-315 
specific alterations indicate biologically relevant heterogeneity in DNA methylation and are 316 
still relevant in the aetiology of disease (45). Additionally, methylation of a particular CpG 317 
position may have a strong influence on transcriptional suppression or expression while 318 
methylation at other CpG sites may have little influence (46). Surprisingly, methylation at the 319 
ACE locus was reduced in response to riboflavin supplementation, which may be expected to 320 
increase gene expression and thereby increase blood pressure, however the effects on 321 
transcription were not analysed in this study and the effect on blood pressure may involve a 322 
complex interplay with other genes and warrants further investigation. Although the present 323 
study demonstrates significant methylation differences of hypertension pathway genes 324 
following supplementation with riboflavin in MTHFR 677TT individuals, further 325 
investigations are required to better understand the interconnections and interactions between 326 
these genes and the resulting effects on blood pressure. 327 
12 
 
The main strength of this study is that it draws on samples from randomised controlled trials, 328 
providing a rigorous tool to examine the effects of riboflavin supplementation on DNA 329 
methylation and enabled us to examine specific changes at CpG sites of interest. 330 
Additionally, our investigation used a robust biomarker, EGRac, to evaluate riboflavin status 331 
in participants, which is rarely reported due to lack of accessible laboratory methods and 332 
labour-intensive pre-analysis sample preparation; our laboratory is one of the few worldwide 333 
to routinely measure EGRac. Biomarker status offers many advantages over estimated dietary 334 
intake which is widely reported to be inherently flawed (47). Furthermore, we adjusted for 335 
several variables in the statistical analysis of the methylation data ensuring that the findings 336 
were not masked by confounding factors. A limitation, however, is that although the 337 
candidate gene approach employed investigated specific hypertension-related genes, further 338 
relevant genes and CpG sites may have been omitted (48) and could potentially be influenced 339 
by riboflavin supplementation.  Despite the limitations of the candidate approach this study 340 
has yielded some interesting results to direct further studies. Further as DNA methylation was 341 
examined in blood we cannot exclude the possibility that methylation patterns identified may 342 
represent an overall effect contributed from the different cell fractions. 343 
 344 
5.0 Conclusion 345 
The findings of this study demonstrate that supplementation with riboflavin (the MTHFR co-346 
factor) in adults with the MTHFR 677TT genotype modulates DNA methylation at key 347 
hypertension-related genes including IGF2 and GNA12. Furthermore, we observed 348 
significant differences in DNA methylation at NOS3 and GNA12 between individuals with 349 
CC and TT genotypes for this polymorphism. The results from this study provide some 350 
preliminary data to indicate that methylation of hypertension related genes may be implicated 351 
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in the mechanism linking MTHFR with blood pressure however further investigations are 352 
required to understand the complex mechanism. Furthermore, this study highlights the 353 
interaction between genetic, epigenetic and environmental factors which could play a 354 
potential role in the prediction of vascular events and in the development of therapeutic 355 
options for the treatment of high blood pressure. Replication of our findings in larger 356 
independent cohorts using a genome-wide approach is required to understand the complex 357 
mechanisms linking this common polymorphism with higher blood pressure and the DNA 358 
methylation response to riboflavin intervention in individuals with the variant MTHFR 359 
677TT genotype. 360 
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Table 1: General characteristics of participants for observational study grouped according to 
MTHFR C677T genotype (n 80) 
 MTHFR C677T Genotype 
 MTHFR 677CC 
(n 40) 
MTHFR 677TT  
(n 40) 
p-value 
Age (yr) 58.3(3.9) 56.8(6.9) 0.215 
Male n (%) 22(55.5) 24(60.0) 0.651 
Smoker n (%) 5(12.5) 6(15.0) 0.745 
Alcohol (%) 28(70.0) 26(65.0) 0.633 
Hypertensive BP n (%) 12(30.0) 22(55.0) 0.024 
BMI (kg/m2) 29.5(4.8) 29.8(4.8) 0.769 
 
Blood pressure (mmHg)    
Systolic BP 132.4(18.3) 143.5(16.0) 0.005 










Data expressed as mean (SD) for continuous variables and frequency (%) for categorical variables. P < 
0.05 considered statistically significant. Categorical variables analysed using chi square statistics, 
independent t-test used for analysing continuous data, Hypertensive status (baseline) defined as blood 
pressure readings (systolic/diastolic) 140 mmHg and or 90 mmHg or greater. 
















Table 2: Baseline DNA methylation in hypertension-related genes stratified by MTHFR 
C677T genotype (n 80) 
   































































































































































































































































































The data are expressed as mean (SEM) with P < 0.05 considered statistically significant. Data was 
analysed using one-way ANCOVA adjusting for covariates: age, sex, smoking status and study 
cohort. ACE, Angiotensin I-converting enzyme; AGTR1, Angiotensin receptor 1; GCK, Glucokinase; 
GNA12, Guanine nucleotide-binding protein, alpha-12; IGF2, Insulin-like growth factor II; MMP9, 
Matrix metalloproteinase 9; NOS3, Nitric oxide synthase 3. 
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Table 3: Determinants of baseline gene-specific methylation in adults stratified by the MTHFR C677T genotype (CC, n = 40; TT, n = 40) 
 Gene-specific DNA methylation 
 AGTR1  GCK  NOS3 
 β P-value  β P-value  β P-value 
MTHFR C677T genotype 0.264 0.026  0.076 0.503  0.256 0.031 
Age 0.009 0.936  0.321 0.004  -0.047 0.678 
Sex -0.070 0.546  0.224 0.047  -0.006 0.957 
Smoker -0.047 0.676  0.117 0.282  0.103 0.359 
Hypertensive status -0.094 0.432  -0.088 0.447  0.088 0.458 
BMI 0.155 0.191  0.006 0.958  0.073 0.538 
Multiple linear regression analysis was conducted with gene-specific DNA methylation as dependent variable. P < 0.05 was considered as statistically 
significant. Regression was performed for each gene with adjustment for significant covariates as appropriate. All genes were investigated; those showing 




Table 4: DNA methylation in hypertension-related genes response to intervention with 
riboflavin in MTHFR 677TT genotype individuals (n 80) 
  
































































































































































































































































































































































































































The data is expressed as mean (SEM), with P < 0.05 considered statistically significant. Data was 
analysed using mixed between-within repeated measures ANCOVA adjusting for covariates: age, sex, 
smoking status and study cohort as covariates. ACE, Angiotensin I-converting enzyme; AGTR1, 
Angiotensin receptor 1; GCK, Glucokinase; GNA12, Guanine nucleotide-binding protein, alpha-12; 
IGF2, Insulin-like growth factor II; MMP9, Matrix metalloproteinase 9; NOS3, Nitric oxide synthase 
3. 
 
 
 
